

12th May, 2025

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) –Successful closure of US FDA Inspection at Piramal Pharma’s manufacturing facility located at Turbhe

Dear Sir/Madam,

Kindly refer to our letter dated 18th February, 2025 regarding US FDA conducted General Good Manufacturing Practices (GMP) inspection at Piramal Pharma Limited's Turbhe facility from 11th February, 2025 to 17th February, 2025.

In furtherance to the aforementioned intimation, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility with VAI (Voluntary Action Indicated).

Receipt of said EIR marks successful closure of the inspection.

This is for your information and records.

Thank you,

Yours truly,
For Piramal Pharma Limited

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com